Advanced Therapy Medicinal Products Market: Overview

Lately, there has been remarkable shift in the therapeutics method. People are inclining towards personalized medication rather than pharmaceutical treatment methods. This is result of advancements in biological therapies. As a result, advanced therapy medicinal products market (ATMP) is emerging. Such products provide solution for conditions with no therapeutic alternatives. This is a key factor driving growth of the advanced therapy medicinal products market across the globe.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6520

At present, regulations for ATMPs is at its budding stage. Extensive research activities has been going on, which is resulting in Investigational New Drug (IND) applications.

The upcoming advanced therapy medicinal products market analysis report provides insight about the upcoming trends and restraining factors likely to shape growth of the market during forecast period (2019-2029). The report also provides a comprehensive analysis of the key companies of the market and offers details about the capacities and competencies of these companies. The market report also focusses on the markets competitive landscape and provides detail of the product portfolio of various companies.

Advanced Therapy Medicinal Products Market: Competitive Analysis

At present, the advanced therapy medicinal products market is growing at a lucrative rate. This growth rate is attributed to recent approval of various advanced therapy medicinal products. Post success of approved products, stakeholders are investing at enormously in clinical trials of advanced therapy medicinal products.

On the other hand, companies operating in the market are adopting various strategies to accelerate the product manufacturing rate. While most of the companies are relying on in-house production of therapies, few players such as Contract Manufacturing Organizations (CMOs) are opting for third-party service providers.

Upsurge in demand for gene therapy has resulted in widening of drug development landscape and rise in the number of new entrants. However, there is lack of production capabilities.

Also, several companies are strengthening their foothold in the global market by strategic alliances and acquiring small CAR T-cell therapy developers.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6520

Some of the key players operating in the advanced therapy medicinal products market are-

Advanced Therapy Medicinal Products Market: Key Trends

Despite high cost of the products, the market is expanding at lucrative rate. The growth rate is attributed to various health benefits provided by new classes of therapies.

Registering clinical benefits and efficiency of the products, stakeholders in the market are developing new strategies to overcome the challenged and boost application of advanced therapy medicinal products

Advanced Therapy Medicinal Products Market: Regional Outlook

Availability of significant number of FDA approved advanced therapy medicinal products in the U.S. has accounted for the prominent share of North America region, in terms of revenue. Recently, approval of products such as Yescarta, Zolgensma, and Kymriah has led to prominent investment in the U.S. advanced therapy medicinal products market.

Europe hold second-largest pharmaceutical market space across the globe. In coming years, cell therapy developers are anticipated to hold prominent share in the Europes drug revenue. Moreover, several academic institutes in Europe are conducting extensive research in early-stage cell therapy. This factor is likely to fuel the regional revenue contribution.

Meanwhile, global manufacturing companies operating in the market are enhancing their reach across Europe. This, in turn, may drive growth in the regional market.

Get Discount on Latest Report @https://www.tmrresearch.com/sample/sample?flag=D&rep_id=6520

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,3739 Balboa St # 1097,San Francisco, CA 94121United StatesTel: +1-415-520-1050

See more here:
Advanced Therapy Medicinal Products Market Statistics, Segment, Trends and Forecast 2029 - Cole of Duty

Recommendation and review posted by Bethany Smith

The novel coronavirus seems to be killing more men than women.

The trend was first noticed in China, experts say, and the higher COVID-19 death rate for men has since been documented in 33 countries, including Germany, Spain and South Korea. But experts dont know whats causing the gap. Is it biological, some quirk of cells and hormones? Is it the result of gendered behaviors that have more to do with sociology than sex chromosomes? Lets break down whats going on, because experts say mens risk level depends on what risks (and which men) youre talking about.

While men account for the majority of COVID-19 cases in some countries but a minority of cases in others, they consistently make up the majority of deaths. Out of 35 countries that have reported their COVID deaths in ways that break out victims by sex, 33 had a male-female death ratio greater than 1, meaning men who were confirmed to have the disease were more likely to die than women who were confirmed to have it, according to data compiled by Global Health 50/50, a independent health equity research organization based at University College London. So far, the mortality disadvantage for men is quite large, said Jennifer Dowd, a professor of demography and population health at the University of Oxford.

Share of COVID-19 patients who died, by gender

Numbers in this table come from different dates, depending on the country and how frequently it updates its publicly available data. Most of the data is dated to April 26-29, though a few countries numbers are from earlier in April. Chinas data is from Feb. 28 and Irans is from March 17.

Source: Global Health 50/50

This dynamic isnt new to medicine. Women have stronger adaptive immune responses and die less of infectious disease their entire lives, starting from infant mortality, Dowd said. In general, womens bodies kick out bacterial and viral invaders faster than mens do, and vaccines work better for women than for men.

To see why, look to hormones and genetics, said Sabra Klein, professor of microbiology and immunology at Johns Hopkins University. Sex hormones appear to play a role determining how well human bodies can fight off disease. In general, estrogens amp up the immune system, while androgens (like testosterone) and progesterone suppress it. Hormones have to interact with cells to do their jobs, Klein said, so cells have a lock and hormones have the key to get in. And, turns out, every immune cell in your body has these kinds of lock-and-key receptors.

Sex chromosomes also play a role. The X chromosome, for example, has 60 genes associated with immune function. Most biological males are born with one X chromosome, but those immune-boosting genes tend to be expressed more frequently in women, who generally have two X chromosomes, Klein said.

But if youre tempted to think those sex differences boil down to men are more likely to die from infectious disease, Klein cautioned that the generalization is not true across the board. Sex differentiation in influenza has been pretty well studied, she told me, and, in that case, womens more aggressive immune systems dont give us an advantage. Having too much of an inflammatory immune response to the flu can actually increase your risk of complications including acute respiratory distress syndrome, when the lungs tiny air sacs, called alveoli, are damaged and fill with fluid. Reproductive-age women do worse, not better, Klein said.

But while researchers know a decent amount about sex differences in influenza, the novel coronavirus is, yes, novel. Any research on it is a work in progress, proceeding without full data. That starts with basic documentation.

On April 28th, the United States had reported 57,318 deaths from the novel coronavirus, but only 31,586 of those deaths had been reported in ways that allowed Global Health 50/50 to break them down by sex. None of the researchers I spoke with knew why that data isnt getting reported. But without it, theyre left to a lot of guesswork and speculation. Its safe to assume that deaths in the U.S. are probably following the patterns seen in many other countries but we dont know for sure that thats true.

Then theres the fact that the variations in how this virus affects people probably isnt just about whats in their chromosomes or hormones. Its also about sociological gender the attitudes, stereotypes and norms that shape the ways people behave and the choices they make.

For example, a 2016 meta-analysis showed that women are about 50 percent more likely than men to start using non-pharmaceutical protective behaviors during a pandemic things like wearing face masks or avoiding public transit. Men, meanwhile, were about 12 percent more likely than women to sign up for vaccines, take antiviral medication, or use other pharmaceutical interventions. Those differences in behavior arent determined by biology, but they could help create variations in how a virus affects men and women.

Rosemary Morgan, a scientist at Johns Hopkins Bloomberg School of Public Health who studies how gender and sex interact with public health, thinks these kinds of effects are happening with COVID-19. But how and to what extent thats unknown. It also probably differs from country to country, thanks to the way gender norms also arent consistent everywhere you go.

Case in point: When data on sex disparities in COVID-19 deaths first began to come in from China, it wasnt clear that the differences in death rates there would mean other counties were going to experience the same thing. Thats because China has particularly gendered smoking habits, Dowd told me. In a 2010 study, 54 percent of Chinese men surveyed were current smokers. In contrast, the same study found that less than 3 percent of Chinese women currently smoked. Although sex differences in COVID-19 death rates have cropped up again in other countries, its likely that this gender disparity in smoking plays a role in why 64 percent of Chinas COVID-19 deaths have been among men even though men account for right around half of Chinas confirmed cases.

Gender norms may also influence the niches where women are getting the disease more than men, despite mens higher death rates. When the Centers for Disease Control and Prevention looked at the characteristics of health care workers who have contracted COVID-19, it found that 73 percent were women. Why are female health care workers getting infected at much higher rates? Part of it likely has to do with their higher odds of exposure.

Nurses jobs put them in close physical contact with patients who have COVID-19 and other infectious diseases, and more than 70 percent of nurses are women. Meanwhile, the personal protective equipment meant to help keep medical workers safe often isnt designed with women in mind. Gloves can be too large. Masks dont always fit womens faces with a tight seal. Gender dynamics could be putting a largely female workforce in harms way.

In the end, regardless of your sex or your gender the risks you face from COVID-19 are probably somewhat unique to you. But if we want to figure out just what, exactly, those risks are, were going to need more data.

See the original post here:
Why Are More Men Than Women Dying Of COVID-19? - FiveThirtyEight

Recommendation and review posted by Bethany Smith

Dr Winnie Njenga, a dermatologist at Kiambu Level 5 Hospital, answers some of the most frequently asked questions around skincare. Pick up skin protection tips, discover some of the common skin problems and learn what suspicious growths might mean.After I turned 30, I developed acne. I have never had to deal with that before. What can I do? How does one deal with adult acne?Adult acne is an interplay of factors, such as your skin type, inflammation and the hormonal milieu. Your dermatologist can assess your risk factors and advise on the best way forward. Remember treatment will vary from person to person. You also need to have your skincare and hair products assessed.I have skin tags; many of them. And I dont like them. Is there anything I can do to slow down their development?Many people develop skin tags. They can be removed by your dermatologist. I would recommend that you practice a healthy lifestyle with a good diet and regular exercise as obesity can make this worse.What are the most common skin problems you deal with?

For More of This and Other Stories, Grab Your Copy of the Standard Newspaper. Read Now

Do not miss out on the latest news. Join the Standard Digital Telegram channel HERE.

Read more from the original source:
Ask a doctor: Is there a treatment that reverses balding? - Standard Digital

Recommendation and review posted by Bethany Smith

The report on Male Hypogonadism Market delivers a succinct analysis on industry size, regional growth and revenue forecasts for the upcoming years. The report further sheds light on significant challenges and latest growth strategies adopted by manufacturers who are a part of the competitive spectrum of this business domain

The report commences with a concise introduction to the Male Hypogonadism market, as well as the present market scenario, market size, a summary of similar industries, and accurate market share estimates.

The driving factors influencing the profitability scale of this business space and the annual growth rate of this industry over the forecast duration have been enumerated in the report. Substantial data with reference to the consumption patterns and rates and patterns of Male Hypogonadism market in conjunction with a conclusive overview of the price analysis is also provided.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/180006

A synopsis of the geographical gist of the geographical landscape unveiled:

Report Objectives:

What are the pivotal highlights of Male Hypogonadism market?

The Male Hypogonadism market report basically is a detailed study of business sphere with respect to the driving forces influencing the dynamics of this industry, consumption value across various geographies, import and export patterns and volumes, and the contribution of major participants toward the Male Hypogonadism market expansion.

The Report Answers the key Questions

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/180006

Read more:
Male Hypogonadism Market Key Players, Product and Production Information analys - News by aeresearch

Recommendation and review posted by Bethany Smith

Company has Partnered with Sterling Medical to Finalize the Development of Cedars-Sinai-Developed 'Healight' Medical Device for Use in Patients with Coronavirus

ENGLEWOOD, CO / ACCESSWIRE / April 27, 2020 / Aytu BioScience, Inc. (AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that it has signed an agreement with Sterling Medical Devices ("Sterling") to finalize the development of Healight, a novel endotracheal catheter, as a potential treatment for coronavirus.

The company announced last week that it licensed exclusive worldwide rights to the Healight technology from Cedars-Sinai for all endotracheal and nasopharyngeal indications. The patent-pending Healight Platform has been in development since 2016 by the Medically Associated Science and Technology (MAST) team at Cedars-Sinai. Following their pre-clinical findings that Healight may be a safe and effective antiviral and antibacterial treatment, the team engaged Sterling to rapidly develop a novel endotracheal device to help combat coronavirus.

"Sterling has been working with the Cedars-Sinai team for the past several weeks on a very accelerated schedule to develop this much needed device," said Dan Sterling, President of Sterling Medical Devices. "We are happy to now be partnering with Aytu to further advance this critical project as fast as we possibly can for the many patients in need."

"The Aytu team is very pleased to be working with Sterling Medical on this important development program and in the fight against coronavirus," stated Josh Disbrow, Chairman and CEO of Aytu BioScience. Disbrow further commented, "Sterling has a stellar reputation as a best-in-class medical device product firm with more than 21 years of experience, over 1,100 projects engineered, with none failing to receive FDA regulatory approval upon submission. Our team is actively engaged with our colleagues at Sterling in an effort to finalize the device development, with hope of enabling human use in the very near future."

The company believes the Healight platform technology has the potential to positively impact outcomes for critically ill patients infected with coronavirus and other infections. Aytu, with support of the team at Cedars-Sinai, is working with the FDA to determine an expedited regulatory process to potentially enable near-term use of the technology initially as a coronavirus intervention for critically ill intubated patients.

About Aytu BioScience, Inc.

Aytu BioScience, Inc. is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The Company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes (i) AcipHex Sprinkle, a granule formulation of rabeprazole sodium, a commonly prescribed proton pump inhibitor; (ii) Cefaclor, a second-generation cephalosporin antibiotic suspension; (iii) Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions; and (iv) Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency. Aytu recently acquired exclusive U.S. distribution rights to the COVID-19 IgG/IgM Rapid Test. This coronavirus test is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma. This point-of-care test has been validated in a 126 patient clinical trial in China and has received CE marking.

Aytu recently acquired Innovus Pharmaceuticals, a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer healthcare products designed to improve men's and women's health and vitality. Innovus commercializes over thirty-five consumer health products competing in large healthcare categories including diabetes, men's health, sexual wellness and respiratory health. The Innovus product portfolio is commercialized through direct-to-consumer marketing channels utilizing the Company's proprietary Beyond Human marketing and sales platform.

Story continues

Aytu's strategy is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit aytubio.com and visit innovuspharma.com to learn about the Company's consumer healthcare products.

About Sterling Medical Devices

Founded in 1998, Sterling Medical Devices (SMD), specializes in the product design and engineering of medical devices for the healthcare industry. Dedicated to resolving their clients' medical device design and engineering challenges, SMD addresses the whole development process, including, product design and human factors, systems, software, electronics, mechanical, quality, and compliance. The company utilizes the latest tools and technology to streamline the engineering process to speed regulatory approval of Class I, II and III devices. To date, the company has spearheaded the production of over 1,100 projects for more than 300 clients. SMD is internationally recognized and is FDA QSR 21, CFR 820, and 21 CFR Part 11 compliant, ISO 13485 registered, and IEC 62304, ISO 14971, IEC 60601, and IEC 62366 compliant. For more information, please visit http://www.sterlingmedicaldevices.com or call 201.227.7569 x2.

Forward-Looking Statement

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as ''may,'' ''will,'' ''should,'' ''forecast,'' ''could,'' ''expect,'' ''suggest,'' ''believe,'' ''estimate,'' ''continue,'' ''anticipate,'' ''intend,'' ''plan,'' or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: market and other conditions, the regulatory and commercial risks associated with introducing the COVID-19 Rapid Test, our ability to enforce the exclusivity provisions of the distribution agreement, the reliability of serological testing in detecting COVID-19, shipping delays and their impact on our ability to introduce the COVID-19 Rapid Test, the ability of the COVID-19 Rapid Test to accurately and reliably test for COVID-19, the manufacturer of the COVID-19 Rapid Test's ability to manufacture such testing kits on a high volume scale, manufacturing problems or delays related to the COVID-19 Rapid Test, our ability to satisfy any labelling conditions or other FDA or other regulatory conditions to sell the COVID-19 Rapid Test Kit, the demand or lack thereof for the COVID-19 Rapid Test Kit, our ability to obtain additional COVID-19 Rapid Tests to meet demand, our ability to secure additional tests if the manufacture of the COVID-19 Rapid Tests is unable to meet demand, the effects of the business combination of Aytu and the Commercial Portfolio and the recently completed merger ("Merger") with Innovus Pharmaceuticals, including the combined company's future financial condition, results of operations, strategy and plans, the ability of the combined company to realize anticipated synergies in the timeframe expected or at all, changes in capital markets and the ability of the combined company to finance operations in the manner expected, the diversion of management time on Merger-related issues and integration of the Commercial Portfolio, the ultimate timing, outcome and results of integrating the operations the Commercial Portfolio and Innovus with Aytu's existing operations, risks relating to gaining market acceptance of our products, obtaining or maintaining reimbursement by third-party payors for our prescription products, the potential future commercialization.

SOURCE: Aytu BioScience, Inc.

View source version on accesswire.com: https://www.accesswire.com/587152/Aytu-BioScience-Signs-Development-Agreement-with-Sterling-Medical-Devices-to-Advance-the-Development-of-Healight-as-a-Potential-Coronavirus-Treatment

See original here:
Aytu BioScience Signs Development Agreement with Sterling Medical Devices to Advance the Development of Healight as a Potential Coronavirus Treatment...

Recommendation and review posted by Bethany Smith

Shawnna Latino had few concerns as she awaited the results of her biopsy for breast cancer in 2015. After all, she was a registered nurse who understood the ramifications of the disease, and she had done all the right things regular self-examinations and never-missed yearly mammograms.

So when a mammogram detected calcifications in one of her breasts, she thought they were simple benign calcium deposits.

When the results came back from the biopsy, I was shocked, she said. She had tested positive for breast cancer.

The diagnosis was particularly troubling because of Shawnnas family medical history, which is fraught with cancer. Her mother at age 70 had been diagnosed with breast cancer just eight months before her daughters test results.

At the same time, Shawnnas brother was battling aggressive prostate cancer, which eventually took his life. Their maternal grandmother had died of cancer, as had the grandmothers five sisters. A maternal aunt had died of pancreatic cancer, and her daughter, Shawnnas cousin, was diagnosed with the same disease soon afterward.

Shawnna Latino with her mom, Dietra Dede Lucas (left), and her daughter, Bailee Norris, during Shawnnas chemo and radiation treatment.

When Shawnna consulted with her oncologist, Dr. Thomas J. Harris at Texas Oncology in Waco, he wanted to conduct genetic testing, something that is done as needed at the oncology clinic.

She thought it unlikely that she might have a gene mutation, which can indicate a high risk of breast and ovarian cancer as well as other cancers. The mutation affects only a small percentage of the population.

However, once more, Shawnna found herself with a positive test result, this time for mutation of the BRCA-2 gene.

I never imagined it would be positive, she said.

They then tested her mother and discovered the same genetic problem. The women found out later that Shawnnas maternal cousin was in the same boat. She has the exact mutation that my mom and I have, she said.

Mutation

BRCA 1 & 2 are tumor suppressor genes that prevent uncontrolled cell growth and help keep normal cells from becoming cancerous. If either is mutated, a woman will have a 40-70% risk of having breast cancer and 27-44% chance of ovarian cancer during her lifetime.

In men, such mutations can result in male breast cancer (6% risk) or prostate cancer (20%). Both genders are also at risk for melanoma and pancreatic cancer.

Just as troubling, if not more so, is the fact that people of either gender with the mutation have a 50% chance of passing it to their children, which keeps the cancer cycle going throughout generations.

The last thing you want to do is pass it on to your child, Shawnna said. Her biggest fear was that her daughter, Bailee Norris, may have inherited the mutation. However, genetic testing showed that Bailee had not, a great relief to her mother.

Dr. Carlos Encarnacin, breast cancer and genetics specialist at Texas Oncology, said, Cancer is a genetic disease, but it is not always inherited.

Most cancers are sporadic, he said, caused by lifestyle choices like smoking or other unknown factors, but some develop through a mutated gene (like BRCA) inherited from either parent.

Dr. Carlos Encarnacin, a breast cancer and genetics specialist at Texas Oncology, says genetic testing has become an integral part of oncology.

The doctors at Texas Oncology treat all types of cancer using radiation and drugs, but they also work to identify cancer risks in a timely manner.

Our focus is early detection and prevention, Encarnacin said.

A person considered at high probability because of family history or other factors should have a risk assessment, starting with an interview and an estimation of risk. If testing is deemed necessary, a blood or saliva test can be done to see if theres a mutation. The price of testing has gone down dramatically, and insurance often covers the cost or at least part of it.

Importance

Is genetic counseling important for much of the population?

Absolutely, Encarnacin said. If a patient had cancer or has family history of cancer, he or she should have a risk evaluation and maybe genetic testing.

He suggests that people discuss this with their family doctor and be referred to a specialist if necessary. Its important that the counseling and testing be administered by those who are specifically trained for it.

Genetics has become an integral part of oncology, and it will keep changing over time, he said. Researchers found the first cancer-related gene, BRCA-1, in the mid-1990s, but new genes related to various types of cancer are being identified regularly.

Reduction of cancer risk in BRCA carriers can be achieved in a couple of ways, including hormone blocker pills or preventative mastectomies.

However, he said of the mastectomy, Not everyone with a BRCA mutation has to choose that. They may prefer an enhanced cancer surveillance program.

Women with BRCA mutations who do not intend to have more children should strongly consider having their ovaries removed to lessen their chance of a deadly ovarian cancer, Encarnacin said.

Decisions

For Shawnna, when she learned of her breast cancer and gene mutation, the choice was clear. Though the cancer was only in one breast, she said, I decided to have both removed and be done with it.

After surgery for the removal and reconstruction, she went through chemo and radiation treatments, continuing to work as a nurse every day except for Wednesdays, her treatment days.

I think that had a lot to do with my well-being, she said.

Genetic testing showed that Shawnna Latinos mom Dietra Dede Lucas also has a gene mutation, but her daughter Bailee Norris does not.

Later that year, she had a complete hysterectomy to reduce the risk of ovarian cancer.

Because she has the BRCA mutation, she is screened each year for pancreatic cancer and also must be seen by a dermatologist once a year to check for melanoma.

In the meantime, Shawnna and her husband, dentist Chad Latino, and children Bailee, Aidan and Tristan are moving on with life by enjoying every day to the fullest. And, along with friends and business partners Scott and Michelle Irwin, they have begun a new enterprise.

The four of them will be keeping their current jobs but are planning to open a hatchet-throwing business whenever the current pandemic subsides. Stumpys Hatchet House, which is in a Waco historic building at 924 Austin Ave., was due to open before the coronavirus hit.

With a laugh, she says of the venture, It was kind of a coincidental thing. Sure, we said. We all have full-time jobs. Lets start a business!

Shawnna has a joyful attitude that is apparent. Of her cancer experiences, she said, There were so many blessings in that journey. I never asked why me? It was always why not me?

She considers genetic testing essential.

Its so important to know your health history and your family history, she said. It can save your life. Knowledge is power, and its very empowering to know about yourself.

As Shawnna found out, sharing your medical history with family is also highly important to alert others to possible inherited genetic mutations.

Read more:
Genetic testing helps find cancer possibilities: Waco nurse dealt with breast cancer caused by mutation - Waco Tribune-Herald

Recommendation and review posted by Bethany Smith

The Global Direct-to-Consumer (DTC) Genetic Testing Market will reach significant CAGR during forecast period 2020-2026. In addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.

The research report on the Direct-to-Consumer (DTC) Genetic Testing market offers a complete study on market share, size, growth aspects and main players. In addition, the report contains brief information on the regional competitive landscape, market trends and drivers, opportunities and challenges, distributors, sales channels, risks and barriers to entry, as well as the analysis of Porters five forces

Information has been added to the report to provide a realistic view of the industry based on data from Direct-to-Consumer (DTC) Genetic Testing manufacturers, i.e. H. Shipping, price, sales, gross profit, business distribution, etc., SWOT analysis, consumer preference, current developments and trends, drivers and limiting factors, company profile, investment opportunities, analysis of the demand gap, market size value / volume, services and products, Porters five models , socio-economic factors, official regulations in the Direct-to-Consumer (DTC) Genetic Testing branch.

Market participants can use the report to take a look at the future of the Direct-to-Consumer (DTC) Genetic Testing market and make significant changes to their operating style and marketing tactics in order to achieve sustainable growth.

Get Sample PDF with Latest Sales & Market Sizing Figures @: http://www.supplydemandmarketresearch.com/home/cod-Brochure

The Report Covers the Following Companies: 23andMe deCODEme DNA DTC GeneByGene Genecodebook Oy Genetrainer MD Revolution Myriad Genetics Navigenics

Market Competition

The competitive landscape of the Direct-to-Consumer (DTC) Genetic Testing market is examined in detail in the report, with a focus on the latest developments, the future plans of the main players and the most important growth strategies that they have adopted. The analysts who compiled the report have created a portrait of almost all of the major players in the Direct-to-Consumer (DTC) Genetic Testing market, highlighting their key commercial aspects such as production, areas of activity and product portfolio.

All companies analyzed in the report are examined on the basis of important factors such as market share, market growth, company size, production, sales and earnings.

Product Type coverage like market size & forecast, diverse ultimatum by region, key consumer profile etc: Genome Data Bank Material Model Individual Health Planning Model Comprehensive Genome Tests Model Medical Precision Tests Model Restricted Trait Tests Model

Direct-to-Consumer (DTC) Genetic Testing market size by Applications Doctor Office Internet Others

The global Direct-to-Consumer (DTC) Genetic Testing market study covers the projection size of the market both in terms of value (Mn/Bn US$) and volume (x units).

The report estimates the lookup of different local distributors in the overall market and provides the market size of the Direct-to-Consumer (DTC) Genetic Testing market using both bottom-up and top-down approaches. To investigate the key players and their market contribution, primary and secondary research has been comprehensively performed.

In addition, all the figures, subdivisions, and shares have been collected with the help of trustworthy sources.

http://www.supplydemandmarketresearch.com/home/purchase?code=

Global Direct-to-Consumer (DTC) Genetic Testing Market by Geography:

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Europe (Turkey, Germany, Russia UK, Italy, France, etc.)

North America (the United States, Mexico, and Canada.)

South America (Brazil etc.)

The Middle East and Africa (GCC Countries and Egypt.)

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Direct-to-Consumer (DTC) Genetic Testing market, to estimate the size of various other dependent submarkets in the overall market.

Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

Highlights of the report:

Scrutinized data of the drivers and restraints affecting the growth of the Direct-to-Consumer (DTC) Genetic Testing market.

Detailed analysis of distribution channels, and consumption patterns, of the global Direct-to-Consumer (DTC) Genetic Testing market.

Comprehensive evaluation of the Direct-to-Consumer (DTC) Genetic Testing market player, which includes strengths, weaknesses, opportunities and threats.

In-depth information regarding the recent R&D projects across various regions and end-use industries.

Up-to-date insights about the trends influencing the Direct-to-Consumer (DTC) Genetic Testing market growth, including ecological preservation, and regulatory norms.

Learn more about this report At: http://www.supplydemandmarketresearch.com/direct-et-1042232

If you are part of this market, then Get to Know how you are perceived in comparison to your competitors. Get an accurate view of your business in Global Direct-to-Consumer (DTC) Genetic Testing Marketplace with latest study published by Supply Demand Market Research.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Read the rest here:
Direct-to-Consumer (DTC) Genetic Testing Market report reviews analysis of key players by size, share, trends, and forecast 2020- 2026 - WhaTech...

Recommendation and review posted by Bethany Smith

AncestryDNA's genetic testing kits are a fantastic way to learn more about yourself, your family, and where you originate from. For a limited time, the kits are available from just $59 at Ancestry's site offering you the opportunity to save as much as $50. The Mother's Day sale there is also being matched at Amazon.

The AncestryDNA genetic testing kit uses your saliva to collect and analyze your DNA. After you send in your sample, the AncestryDNA lab will analyze it and uncover your ethnic mix. It's based on a DNA network that is six million strong and growing and covers more than 165 regions worldwide. It's down to $59 which is $40 off its regular price.

The enhanced AncestryHealth kit tells you quite a bit more than the standard ethnicity test from AncestryDNA. Where the standard kit aims to discover where you're from and your "Ethnicity Estimate", the AncestryHealth kit takes things a step further by looking at your DNA and how it may influence certain health conditions, which could be important to know about early. You'll also receive health and wellness reports and carrier status reports, as well as access to genetic counseling resources and a Family Health History Tool.

There are tons of DNA testing kits out there, but AncestryDNA's are some of the most popular and for good reason. They excel at genealogy and matching you up with your ancestors in comparison to others, and today's prices are a no-brainer for the level of in-depth knowledge it will bring, especially if you're looking for a more interesting Mother's Day gift.

The deals are only available until May 10 when prices will rise.

We may earn a commission for purchases using our links. Learn more.

Read more from the original source:
Save up to $50 on AncestryDNA and AncestryHealth testing kits until Mother's Day - Android Central

Recommendation and review posted by Bethany Smith

The research report on Genetic Testing Devices Market provides comprehensive analysis on market status and development pattern, including types, applications, rising technology and region. Genetic Testing Devices Market report covers the present and past market scenarios, market development patterns, and is likely to proceed with a continuing development over the forecast period. The report covers all information on the global and regional markets including historic and future trends for market demand, size, trading, supply, competitors, and prices as well as global predominant vendors information.

Get Sample copy: https://www.reportspedia.com/report/life-sciences/global-genetic-testing-devices-market-report-2019,-competitive-landscape,-trends-and-opportunities/28940 #request_sample

This market research report on the Genetic Testing Devices Market is an all-inclusive study of the business sectors up-to-date outlines, industry enhancement drivers, and manacles. It provides market projections for the coming years. It contains an analysis of late augmentations in innovation, Porters five force model analysis and progressive profiles of hand-picked industry competitors. The report additionally formulates a survey of minor and full-scale factors charging for the new applicants in the market and the ones as of now in the market along with a systematic value chain exploration.

An outline of the manufacturers active within the Genetic Testing Devices Market, consisting of

Myriad GeneticsCepheidLuminexSeegeneBioRad LaboratoriesWaferGen BiosystemsIntegraGenBioMerieuxInterpace DiagnosticsQiagenElitechElitechAbbott LaboratoriesBiocartisPerkinElmerRoche DiagnosticsEKF DiagnosticsQuest Diagnostics

The Genetic Testing Devices Market Segmentation by Type:

Type 1Type 2Type 3

The Genetic Testing Devices Market Segmentation by Application:

Application 1Application 2Application 3

Market Segment by Regions, regional analysis covers

Get Upto 40% discount on this report Click Here @ https://www.reportspedia.com/discount_inquiry/discount/ 28940

The competitive landscape of the Genetic Testing Devices Market is discussed in the report, including the market share and new orders market share by company. The report profiles some of the leading players in the global market for the purpose of an in-depth study of the challenges faced by the industry as well as the growth opportunities in the market. The report also discusses the strategies implemented by the key companies to maintain their hold on the industry. The business overview and financial overview of each of the companies have been analyzed.

This report provide wide-ranging analysis of the impact of these advancements on the markets future growth, wide-ranging analysis of these extensions on the markets future growth. The research report studies the market in a detailed manner by explaining the key facets of the market that are foreseeable to have a countable stimulus on its developing extrapolations over the forecast period.

Key questions answered in this research report:

Table of Contents:

Global Genetic Testing Devices Market Research Report

Chapter 1 Genetic Testing Devices Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

.CONTINUED FOR TOC

Get Full Table of content @ https://www.reportspedia.com/report/life-sciences/global-genetic-testing-devices-market-report-2019,-competitive-landscape,-trends-and-opportunities/28940 #table_of_contents

If you have any special requirements, please let us know and we will offer you the report as you want.

More:
Global Genetic Testing Devices Market Development, Market Trends, Key Driven Factors, Segmentation And Forecast To 2020-2026 Cole Reports - Cole of...

Recommendation and review posted by Bethany Smith

Futuristic Reports, The growth, and development of Global Direct-to-Consumer (DTC) Genetic Testing Market Report 2020 by Players, Regions, Type, and Application, Forecast to 2026 provides industry analysis and forecast from 2020-2026. Global Direct-to-Consumer (DTC) Genetic Testing Market analysis delivers important insights and provide a competitive and useful advantage to the pursuers. Simultaneously, we classify different Direct-to-Consumer (DTC) Genetic Testing market based on their definitions. The downstream, and upstream scrutiny are also carried out. Each segment includes an in-depth explanation of the factors that are useful to drive and restrain it.

Global Direct-to-Consumer (DTC) Genetic Testing Market Organizations are confronting issues in keeping their offices completely useful because of a lack of staff and assets in the midst of the COVID-19 (Coronavirus) flare-up. Get a hands-on over key drivers and menace to the Direct-to-Consumer (DTC) Genetic Testing market to prepare your company future-ready the pandemic. Profits out report at exciting prices to learn new opening doors that Direct-to-Consumer (DTC) Genetic Testing players can gain by during and after the Coronavirus emergency.

Key Players Mentioned in the study are Laboratory Corporation of America, Myriad Genetics, Color Genomics, Pathway Genomics, 23andMe, Helix, WeGene, African Ancestry, Gene by Gene, Thermo Fisher, MapMyGenome, Quest Diagnostics

For Better Understanding, Download FREE Sample Copy of Direct-to-Consumer (DTC) Genetic Testing Market Report @ https://www.futuristicreports.com/request-sample/31919

Key Issues Addressed by Direct-to-Consumer (DTC) Genetic Testing Market: It is very significant to have segmentation analysis to figure out the essential factors of growth and development of the market in a particular sector. The report offers well summarized and reliable information about every segment of growth, development, production, demand, types, application of the specific product which will be useful for the player to focus and highlight.

Businesses Segmentation of Direct-to-Consumer (DTC) Genetic Testing Market:

On the basis on the applications, this report focuses on the status and Direct-to-Consumer (DTC) Genetic Testing outlook for major applications/end users, sales volume, and growth rate for each application, including-

On-line Sales Doctors Office

On the basis of types/products, this Direct-to-Consumer (DTC) Genetic Testing report displays the revenue (Million USD), product price, market share, and growth rate of each type, split into-

Disease Risk and Health Ancestry or Genealogy Kinship Lifestyle

Grab Best Discount on Direct-to-Consumer (DTC) Genetic Testing Market Research Report [Single User | Enterprise Users] @ https://www.futuristicreports.com/check-discount/31919

Here is the Quick Overview of Report:

Market Representation: A situation of the business, Analysis, Main players, Size, SWOT analysis 2020 to 2026. Regional Scope: North America (U.S., Mexico, Canada), Europe (Germany, U.K., France, Italy, Spain, Russia, etc), Middle East & Africa (Saudi Arabia, South Africa, etc), South America (Brazil, Argentina, etc) Methodology: Integration of Qualitative and Quantitative research analysis. Report Coverage: Opportunities, Challenges, Market Size, Statistics, Restraints, Drivers, Limits, Market Share, and Current Trends. Forecast Period: 2020-2026

Direct-to-Consumer (DTC) Genetic Testing Market Regional Analysis Includes:

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) North America (the United States, Mexico, and Canada.) South America (Brazil etc.) The Middle East and Africa (GCC Countries and Egypt.)

Direct-to-Consumer (DTC) Genetic Testing Insights that Study is going to Provide:

Current economy opportunities, outline, outlook, challenges, and trends and market trends, dimension, and expansion, aggressive evaluation, major competitors; The report provides a comprehensive evaluation of changing Direct-to-Consumer (DTC) Genetic Testing aggressive energetic; The analysis acknowledges that the sector players key drivers of both conflicts and Direct-to-Consumer (DTC) Genetic Testing growth assess the impact of limitations as well as the opportunities on the sector; Data regarding Direct-to-Consumer (DTC) Genetic Testing industry share by every item fragment, alongside their reasonable worth, have been served in the report; Supply-demand ratio analysis in different end-user industries; Thorough assessment and Technological advances expected to influence market growth in each region;

Inquire More Before Buying @ https://www.futuristicreports.com/send-an-enquiry/31919

For More Information Kindly Contact:

Futuristic ReportsTel: +1-408-520-9037Email: [emailprotected]Media Release: https://www.futuristicreports.com/press-releases

Follow us on Blogger @ https://futuristicreports.blogspot.com/

Read more:
Direct-to-Consumer (DTC) Genetic Testing Market 2020 Strategic Insights and Impact Analysis | Laboratory Corporation of America, Myriad Genetics,...

Recommendation and review posted by Bethany Smith

MarketsandResearch.biz adds a new report titled Global Direct-to-Consumer Genetic Testing (DTC-GT) Market 2020 by Company, Regions, Type and Application, Forecast to 2026 to its online database. The report offers a detailed overview of the factors, the latest market insights with upcoming trends, and breakdown of the products and services. The report presents information on industry trends, top manufacturers, product, material and application, and manufacturers. The study provides key statistics on the market status, size, share, growth factors of the global Direct-to-Consumer Genetic Testing (DTC-GT) market. The report is formulated with respect to the regional landscape of the market incorporating extensive details about the types and application spectrums of this business space. The document covers the emerging players data, including competitive situation, sales, revenue, and global market share.

Market Outline:

The report analyzes the global Direct-to-Consumer Genetic Testing (DTC-GT) market size and share of each separate segment in the market. Substantial information about the company revenue, production, price, as well as gross margins has been provided. In addition, it delivers details regarding the basic information of every prominent rival in the business, manufacturing base, and the business overview, as well as SWOT examination, sales, value, capacity, regional market examination, and market forecast for 2020 to 2026 time-period. The key geographical regions are analyzed in terms of the parameters such as production, market share in terms of the manufacturers as well as with regards to application and type. A detailed analysis of the market drivers and the emerging regional markets has also been segmented separately in the report.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/54613

Based on the product types, market types split into: Over-the-Counter (OTC) Channel, Online Channel

By application, the market is split into: Ancestry-based Genetic Tests, Health and Wellness-based Genetic Tests, Entertainment-based Genetic Tests,

Our best analysts have surveyed the market report with the reference of inventories and data given by the key players: Family Tree DNA, MyHeritage, EasyDNA, Ancestry.com LLC, 24Genetics, Dante Labs, Atlas Biomed, Genebase, Mapmygenome,

Market size segmentation by region & countries: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Executive Outline: This section comprises the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers. It discusses gross margin, sales, revenue, production, market share, CAGR, and market size by region. The report offers a complete forecast of the global Direct-to-Consumer Genetic Testing (DTC-GT) Market by product, application, and region.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/54613/global-direct-to-consumer-genetic-testing-dtc-gt-market-2020-by-company-regions-type-and-application-forecast-to-2026

What Benefits Does This Report Provide?

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

Read this article:
Global Direct-to-Consumer Genetic Testing (DTC-GT) Market 2020 by Company, Regions, Type and Application, Forecast to 2026 - Cole of Duty

Recommendation and review posted by Bethany Smith

Dr Luyun Jiang, Technology Analyst at IDTechEx, recently published this article following the release of the new IDTechEx report, "COVID-19 Diagnostics".

Viruses were once known as "contagious living fluids", strange infectious substances capable of slipping through the finest of filters unnoticed. SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic is indeed slipping through every layer of society, leaving behind severe public health and economic crises. Unlike in the influenza pandemic in 1918, today we are better equipped to identify the elusive bug, with the toolbox of molecular diagnostics and lateral flow assays.

Since the full genome sequencing of the SARS-CoV-2, many national laboratories have identified, in record time, regions of the genome amenable for genetic testing. The golden standard adopted by national laboratories around the world following the WHO protocol to detect the virus in individuals, is based on detecting genetic material specific to SARS-CoV-2 viruses in a person's nasopharyngeal secretions. The main tool for such genetic tests is the Reverse Transcription Polymerase Chain Reaction (RT-PCR). Primer strands that hybridise specifically to the SARS-CoV-2 genome, together with fluorescent probes, help amplify and detect the viral load present in a patient. RT-PCR, normally performed in a real-time quantitative qRT-PCR machine for live fluorescent read-out, constitutes the core element of the testing effort being deployed at the moment across the globe. Clinical laboratories with the necessary equipment and technical know-how to perform RT-PCR are leading this diagnosis effort.

However, not all countries are prepared, neither logistically or with enough equipment and capacity to perform mass testing. An important bottleneck is the short supply of certain ancillary reagents needed to prepare samples for RT-PCR test. RNA extraction kits, for example, are needed for extracting the viral RNA from the sample. The shortage of such supplies, the long processing time and the need to become self-sufficient, has led to many laboratories to try to circumvent some steps in the protocol and to come up with new approaches to reach the testing targets that have been set by policymakers and healthcare officials.

The need for universal and massive testing across the population has led to a race for technology innovations for COVID-19 diagnostics. The newly launched IDTechEx report, "COVID-19 Diagnostics", surveys the technology landscape, with an in-depth analysis of the technology innovations that are enabling a quick access to COVID-19 diagnosis in response to the global pandemic.

Point-of-care molecular diagnostics (POC MDx) are portable devices that perform molecular diagnosis away from central labs. Microfluidics is the key technology behind POC MDx, which controls the motion of small amounts of fluids in microchannels. Microfludic cartridges enable the miniaturisation of devices and introduces automation in the sample handling and detection processes. Some POC MDx devices use isothermal amplification of nucleic acid as an alternative to PCR devices. Isothermal amplifaction bypasses the need of thermal cycling and reduces the detection time from around 2 hours to just 5 min (Abbott ID Now system). Various isothermal amplifaction methods have been adopted for COVID-19 diagnostics. Complex design and unspecific amplification hinder the widespread use of this method. "COVID-19 Diagnostics" provides a deep insight and comparison into the technologies, innovations and current progress on POC MDx and isothermal amplification.

Apart from the time consuming thermal cycling, real-time fluorescent detection is another limitation for low-cost and portable diagnosis tools. Lateral flow assays (both fluorescent or colorimetric), electrochemical detection and microbead-based arrays are integrated with thermal cyclers (PCR reaction) to detect the amplified genetic products. These hybrid systems enable faster, cheaper and palm-size devices for COVID-19 detection at the expense of sensitivity and specificity. More recently, CRISPR-Cas (gene-editing tool based on specific gene recognition) and DNA sequencing techniques show the potential for highly sensitive and selective hybrid systems, as highlighted in "COVID-19 Diagnostics".

Resonating with the message of the WHO director general: "test, test and test", these innovations offer the tools to stop the current outbreak, as well as to prevent future outbreaks, by effective diagnostics and surveillance testing.

For more information, please visit http://www.IDTechEx.com/COVID or contact us at research@IDTechEx.com.

Follow this link:
Fighting the COVID-19 fire with molecular diagnostics innovations - Cambridge Network

Recommendation and review posted by Bethany Smith

New York, April 30, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Hematologic Malignancies Testing Market: Focus on Product, Disease, Technology, End User, Region/Country Data and Competitive Landscape Analysis and Forecast, 2019-2025" - https://www.reportlinker.com/p05829157/?utm_source=GNW What are the underlying structures resulting in the emerging trends within the global hematologic malignancies testing market? How is each segment expected to grow in the global hematologic malignancies testing market during the forecast period and what is the estimated revenue to be generated by each of the segments by the end of 2025? What are the key developmental strategies which are implemented by the major players in order to sustain in the competitive market? What are the key regulatory implications in developed and developing regions for hematologic malignancies testing? Who are the leading players with significant offerings to the global hematologic malignancies testing market? What is the current market dominance for each of these leading players? What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2019-2025? What are the key applications in global hematologic malignancies testing market? What are the major segments of these applications? Which are the dominant disease areas of the global hematologic malignancies testing market? Which is the fastest growing disease area in the global hematologic malignancies testing market? Who are the key manufacturers and service providers in the global hematologic malignancies testing market, and what are their contributions? What is the growth potential of each major hematologic malignancies testing solution provider? What is the scope of the global hematologic malignancies testing market in North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa?

Global Hematologic Malignancies Testing Market Forecast, 2019-2025

The hematologic malignancies testing industry analysis projects the market to grow at a significant CAGR of 15.24% during the forecast period, 2019-2025. The hematologic malignancies testing market generated $1,754.8 million revenue in 2018, in terms of value.

The hematologic malignancies testing market growth has been primarily attributed to the major drivers in this market such as rising incidence of hematologic malignancies, increasing adoption of inorganic growth strategies in the market, favorable reimbursement scenario in the global hematologic malignancies testing market, and increasing funding in hematologic malignancies testing market.However, there are significant challenges which are restraining the market growth.

These challenges include high pricing pressure, lack of trained professionals, and issues pertaining to the analytical validity of genetic testing for cancers.

Expert QuoteThe development of specialized kits has achieved huge success over the past year with NGS and FISH based kits now available across major regions proving the potential to screen malignancies at an early stage.

Scope of the Market Intelligence on Hematologic Malignancies Testing MarketThe hematologic malignancies testing market report provides a holistic view of the market in terms of various factors influencing it, including product optimization, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global hematologic malignancies testing market.

Market SegmentationThe hematologic malignancies testing market segmentation (on the basis of product) is further segmented into kits and services.

The hematologic malignancies testing market segmentation (on the basis of disease) is segmented into leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, and myelodysplastic syndromes.

The hematologic malignancies testing market segmentation (on the basis of technology) is segmented into next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC).

The hematologic malignancies testing market segmentation (on the basis of end user) is segmented into specialty clinics and hospitals, diagnostic laboratories, reference laboratories, and research institutions.

Key Companies in the Hematologic Malignancies Testing MarketThe key manufacturers who have been contributing significantly to the Hematologic malignancies testing market include Abbott Laboratories, Adaptive Biotechnologies, ArcherDX, Inc., ARUP Laboratories, ASURAGEN, INC., Bio-Rad Laboratories, Inc., Cancer Genetics Inc., Sysmex Corporation, F. Hoffmann-La Roche AG, Illumina, Inc, Invivoscribe, Inc., Invitae Corporation, ICON plc, NeoGenomics Laboratories, Inc., and QIAGEN N.V., among others.

Countries Covered North America U.S. Canada Europe Germany U.K. France Italy Spain Rest-of-Europe Asia-Pacific China Japan India Australia Singapore Rest-of-APAC Rest-of-the-World Latin America Middle East and AfricaRead the full report: https://www.reportlinker.com/p05829157/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read more here:
The hematologic malignancies testing industry analysis by BIS Research projects the market to grow at a significant CAGR of 15.24% during the forecast...

Recommendation and review posted by Bethany Smith

An urgent warning has been issued to people living in a western Sydney local government area after health authorities identified a strain of COVID-19 responsible for more than a dozen deaths.

People in the Penrith LGA have been asked to come forward for testing after the strain was identified to have been associated with known COVID-19 clusters.

The strain of the virus is the same one thats been identified at the Newmarch House in Caddens, where 59 people have tested positive for COVID-19 and 13 people have died.

Were uring people in the Penrith local government area to be a focus for increased testing, NSW Chief Medical Officer Dr Kerry Chant said on Friday.

In the video below: NSW Premier confirms nine new coronavirus cases

We are aware that our genetic testing of the virus has indicated there has been a virus strain of COIVD-19 circulating in that broader community and we have seen it enter, for instance, the Newmarch house, but also its been associated with other clusters in that area.

So anyone in the Penrith LGA, I particularly urge you, if youve got respiratory symptoms, come forth and get tested.

Premier Gladys Berejiklian said she wants at least 8,000 people to come forward for testing every day across the state and she doesnt want to see a dip on the weekend.

Our goal is to have as many people tested every day of the week as possible and we want to get close to that 8000 number and even exceed it, she told reporters on Friday.

So please come forward even if you have the mildest symptoms.

More on 7NEWS.com.au

You dont need to wait until Monday. You could be unintentionally passing on the disease without knowing you have it.

Nine new cases of coronavirus were announced on Friday, bringing the states total number of cases to 3,025.

Of the new cases, three are from a known cluster or source, one was acquired overseas and another one remains under investigation.

View post:
Coronavirus in NSW: Penrith residents urged to get tested as COVID-19 strain behind deadly outbreak spreads - 7NEWS.com.au

Recommendation and review posted by Bethany Smith

The global Direct-to-Consumer (DTC) Genetic Testing Market is expected to surge at a steady CAGR in the coming years.The publication offers an insightful take on the historical data of the market and the milestones it has achieved. The report also includes an assessment of current market trends and dynamics, which helps in mapping the trajectory of the global Direct-to-Consumer (DTC) Genetic Testing market. Analysts have used Porters five forces analysis and SWOT analysis to explain the various elements of the market in absolute detail. Furthermore, it also studies the socio-economic factors, political changes, and environmental norms that are likely to affect the global Direct-to-Consumer (DTC) Genetic Testing market.

A recent market study published by Report Hive Research discusses the current and future prospects of the Direct-to-Consumer (DTC) Genetic Testing market. Further, the report includes an in-depth COVID-19 pandemic analysis and various factors that are likely to control the growth trajectory of the Direct-to-Consumer (DTC) Genetic Testing market in the upcoming years. In addition, a qualitative and quantitative assessment of the various market segments is enclosed in the report and accurately represented in the form of tables, graphs, and figures. In addition, the information has analysed with the help of primary as well as secondary research methodologies to offer a holistic view of the target market. Likewise, the Direct-to-Consumer (DTC) Genetic Testing Market report offers an in-house analysis of global economic conditions and related economic factors and indicators to evaluate their impact on the Direct-to-Consumer (DTC) Genetic Testing Market historically.

The Direct-to-Consumer (DTC) Genetic Testing market study published in the report is in a chapter-wise format to ease of the readability and complexity of the data covered. Each chapter is further categorized into its respective segments containing well-structured data. The competitive scenario displayed includes major market player details such as, company profile, end-user demand, import/export volume, sales data, etc. The report also covers the business strategies applied by different players, which will be a great addition for smart business decisions.

Request a sample of this report @ https://www.reporthive.com/request_sample/2292341

This study covers following key players:

23andMedeCODEmeDNA DTCGeneByGeneGenecodebook OyGenetrainerMD RevolutionMyriad GeneticsNavigenics

Essential Findings of the Report

The report is a mindful assortment of vital factors that lend versatile cues on market size and growth traits, besides also offering an in-depth section on opportunity mapping as well as barrier analysis, thus encouraging report readers to incur growth in global Direct-to-Consumer (DTC) Genetic Testing Market. This detailed report on Direct-to-Consumer (DTC) Genetic Testing Market largely focuses on prominent facets such as product portfolio, payment channels, service offerings, applications, in addition to technological sophistication. All the notable Direct-to-Consumer (DTC) Genetic Testing Market specific dimensions are studied and analysed at length in the report to arrive at conclusive insights. Apart from highlighting these vital realms, the report also includes critical understanding on notable developments and growth estimation across regions at a global context in this report on Direct-to-Consumer (DTC) Genetic Testing Market.

Besides these aforementioned factors and attributes of the Direct-to-Consumer (DTC) Genetic Testing Market, this report specifically decodes notable findings and concludes on innumerable factors and growth stimulating decisions that make this Direct-to-Consumer (DTC) Genetic Testing Market a highly profitable. A thorough take on essential elements such as drivers, threats, challenges, opportunities are thoroughly assessed and analysed to arrive at logical conclusions. Additionally, a dedicated section on regional overview of the Direct-to-Consumer (DTC) Genetic Testing Market is also included in the report to identify lucrative growth hubs. These leading players are analysed at length, complete with their product portfolio and company profiles to decipher crucial market findings.

Market segment by Type, the product can be split into:

Genome Data Bank Material ModelIndividual Health Planning ModelComprehensive Genome Tests ModelMedical Precision Tests ModelRestricted Trait Tests Model

Market segment by Application, split into:

Doctor OfficeInternetOthers

The report also lists ample correspondence about significant analytical practices and industry specific documentation such as SWOT and PESTEL analysis to guide optimum profits in Direct-to-Consumer (DTC) Genetic Testing Market. In addition to all of these detailed Direct-to-Consumer (DTC) Genetic Testing Market specific developments, the report sheds light on dynamic segmentation based on which Direct-to-Consumer (DTC) Genetic Testing Market has been systematically split into prominent segments encompassing type, application, technology, as well as region specific segmentation of the Direct-to-Consumer (DTC) Genetic Testing Market.

Some Major TOC Points:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and ApplicationContinued

Why Purchase from Report Hive Research?

For Enquiry before buying [emailprotected] https://www.reporthive.com/request_customization/2292341

Get in Touch with Us :

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.comEmail: [emailprotected]Phone:+1 312-604-7084

Why Go For Report Hive Research?

Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Read more from the original source:
Direct-to-Consumer (DTC) Genetic Testing Market 2020 (Impact of COVID-19): Which product is expected to gain the highest share? - Latest Herald

Recommendation and review posted by Bethany Smith

Global Predictive Genetic Testing market report presents an overview based on the historic data. Report provides market key segmentation such as product type, industry, key regions and key companies. On the basis of historic data, market size has been forecasted in terms of revenue from base year 2019 to 2025. Research report includes in detailed study of growth factors, restrains, opportunities, technological innovations and trends of the global Predictive Genetic Testing market. Report also covers the impact of drivers and restrains region and country wise and the opportunities during the forecast period.

Top Leading Key Players are:Agilent, Technologies, Inc., BGI Genomics, F.Hoffman-La Roche Ltd., Genes In Life., Invitae Corporation, Illumina, Inc., 23andMe, Myriad Genetics, Inc., Pathway Genomics and Thermo Fisher Scientific, Inc.

Get Sample Copy of this Report:https://www.adroitmarketresearch.com/contacts/request-sample/1276

In addition, report on global Predictive Genetic Testing market presents strategic analysis and ideas for new entrants using historic data study. Thus report provides estimation about the market size, revenue, sales analysis and opportunities based on the past data for current and future market status. Report covers analysis of different enterprises as part of global Predictive Genetic Testing market. There are some important tools for any market movement. Also report forecasts the market size of global Predictive Genetic Testing market in Compound Annual Growth Rate in terms of revenue during the forecast period.

The main objective of this research report is to present the comprehensive analysis about the factors which are responsible for the growth of the global Predictive Genetic Testing market. The study report covers all the recent developments and innovations in the market for a Predictive Genetic Testing. The global Predictive Genetic Testing market is likely to provide insights for the major strategies which is also estimated to have an impact on the overall growth of the market. Several strategies such as the PESTEL analysis and SWOT analysis is also being covered for the global market. These strategies have an impact on the overall market.

Browse the complete report @https://www.adroitmarketresearch.com/industry-reports/predictive-genetic-testing-market

The research report on global Predictive Genetic Testing market ensures users to remain competitive in the market. Also report helps to identify the new innovations and developments by existing key players to increase the growth of the global Predictive Genetic Testing market. This market study report covers all the geographical regions where competitive landscape exists by the players such as North America, Europe, Latin America, Asia-Pacific and Middle East Africa. Thus report helps to identify the key growth countries and regions.

In addition, study report covers all the important geographical regions which have good market growth of global Predictive Genetic Testing market. Government organizations and policy makers are taking initiatives to promote the global Predictive Genetic Testing market thus it is boosting the growth of global Predictive Genetic Testing market. Furthermore, report presents the end users on the basis of enterprise size for the global Predictive Genetic Testing market. Report is beneficial for any user of any department as report provides strategic analysis for the expansion of the business cross the globe.

For Any Query on the Predictive Genetic Testing Market:https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1276

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Read the original post:
Predictive Genetic Testing Market 2020 Size By Product Types, End-Users, Regional Outlook, Growth Potential, Price Trends And Forecast To 2025 -...

Recommendation and review posted by Bethany Smith

-Enrollment ongoing in clinical trials of CTX001 for patients with severe hemoglobinopathies-

-Enrollment ongoing in clinical trial of CTX110, targeting CD19+ malignancies-

-Began treating patients in clinical trial of CTX120, targeting B-cell maturation antigen (BCMA)-

-IND and CTA approved for CTX130, wholly-owned allogeneic CAR-T cell therapy targeting CD70-

-Received $25 million milestone payment from DMD/DM1 collaboration with Vertex in April 2020-

ZUG, Switzerland and CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics(NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the first quarter ended March 31, 2020.

"We made substantial progress in the last quarter despite the challenges posed by COVID-19. We are now progressing five cell therapy clinical trials in parallel targeting hemoglobinopathies and various cancers," said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics. "Our CTX001 and CTX110 programs continue to enroll patients, and we expect to report data for these programs this year. We are pleased to have begun treating patients in our CTX120 trial for the treatment of relapsed or refractory multiple myeloma and we expect to begin treating patients in our CTX130 trial in renal cell carcinoma and T-cell and B-cell hematologic malignancies in the second half of this year. Despite these unprecedented times, we continue to execute on our programs and we remain focused on our commitment to patients and their families."

Recent Highlights and Outlook

Title: Dual Guide CRISPR/Cas9 Editing of the CCR5 Gene Provides Complete Protection Against HIV in Humanized Mouse Models (abstract #1046)Session Title: Gene Targeting and Gene CorrectionDate and Time: Thursday, May 14, 2020; 5:30 PM - 6:30 PM

Title: Multiplexing of Up to 10 Gene Edits Using CRISPR/Cas9 to Generate CAR-T Cells with Improved Function (abstract #1151)Session Title: Cancer - Immunotherapy, Cancer VaccinesDate and Time: Thursday, May 14, 2020; 5:30 PM - 6:30 PM

First Quarter 2020 Financial Results

About CTX001CTX001 is an investigational ex vivo CRISPR gene-edited therapy that is being evaluated for patients suffering from TDT or severe SCD in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is a form of the oxygen-carrying hemoglobin that is naturally present at birth and is then replaced by the adult form of hemoglobin. The elevation of HbF by CTX001 has the potential to alleviate transfusion requirements for TDT patients and painful and debilitating sickle crises for SCD patients.

CTX001 is being developed under a co-development and co-commercialization agreement between CRISPR Therapeutics and Vertex.

About CTX110CTX110 is a healthy donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19, or CD19, for the treatment of CD19+ malignancies. A wholly-owned asset of CRISPR Therapeutics, CTX110 is being investigated in a clinical trial designed to assess the safety and efficacy of CTX110 for the treatment of relapsed or refractory B-cell malignancies. The multi-center, open-label clinical trial is designed to enroll up to 95 patients and investigate several dose levels of CTX110.

About CTX120CTX120 is a healthy donor-derived gene-edited allogeneic CAR-T therapy targeting B-cell maturation antigen, or BCMA. A wholly-owned asset of CRISPR Therapeutics, CTX120 is being investigated in a clinical trial designed to assess the safety and efficacy of CTX120 for the treatment of relapsed or refractory multiple myeloma. The multi-center, open-label clinical trial is designed to enroll up to 80 patients and investigate several dose levels of CTX120.

About CTX130CTX130 is a healthy donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 70, or CD70, an antigen expressed on various solid tumors and hematologic malignancies. A wholly-owned asset ofCRISPR Therapeutics, CTX130 is being developed for the treatment of both solid tumors, such as renal cell carcinoma, and T-cell and B-cell hematologic malignancies.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

CRISPR Forward-Looking StatementThis press release may contain a number of "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding CRISPR Therapeutics' expectations about any or all of the following: (i) potential impacts due to the coronavirus pandemic; (ii) the safety, efficacy and clinical progress of CRISPR Therapeutics' various clinical programs including CTX001, CTX110, CTX120 and CTX130; (iii) the status of clinical trials (including, without limitation, the timing of filing of clinical trial applications and INDs, any approvals thereof, the timing of commencement of clinical trials and the expected timing of data releases), development timelines and discussions with regulatory authorities related to product candidates under development by CRISPR Therapeutics and its collaborators; (iv) the number of patients that will be evaluated, the anticipated date by which enrollment will be completed and the data that will be generated by ongoing and planned clinical trials, and the ability to use that data for the design and initiation of further clinical trials; (v) the intellectual property coverage and positions of CRISPR Therapeutics, its licensors and third parties as well as the status and potential outcome of proceedings involving any such intellectual property; (vi) the sufficiency of CRISPR Therapeutics' cash resources; (vii) the expected benefits of CRISPR Therapeutics' collaborations; and (viii) the therapeutic value, development, and commercial potential of CRISPR/Cas9 gene editing technologies and therapies. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects" and similar expressions are intended to identify forward-looking statements. You are cautioned that forward-looking statements are inherently uncertain. Although CRISPR Therapeutics believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the potential impacts due to the coronavirus pandemic such as (x) delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; (y) the timing and progress of clinical trials, preclinical studies and other research and development activities; and (z) the overall impact of the coronavirus pandemic on its business, financial condition and results of operations; the potential for initial and preliminary data from any clinical trial (including CTX001, CTX110, CTX120 and CTX130) not to be indicative of final trial results; the risk that the initial data from a limited number of patients (as is the case with CTX001 at this time) may not be indicative of results from the full planned study population; the outcomes for each CRISPR Therapeutics' planned clinical trials and studies may not be favorable; that one or more of CRISPR Therapeutics' internal or external product candidate programs will not proceed as planned for technical, scientific or commercial reasons; that future competitive or other market factors may adversely affect the commercial potential for CRISPR Therapeutics' product candidates; uncertainties inherent in the initiation and completion of preclinical studies for CRISPR Therapeutics' product candidates; availability and timing of results from preclinical studies; whether results from a preclinical trial will be predictive of future results of the future trials; uncertainties about regulatory approvals to conduct trials or to market products; uncertainties regarding the intellectual property protection for CRISPR Therapeutics' technology and intellectual property belonging to third parties, and the outcome of proceedings (such as an interference, an opposition or a similar proceeding) involving all or any portion of such intellectual property; and those risks and uncertainties described under the heading "Risk Factors" in CRISPR Therapeutics' most recent annual report on Form 10-K, and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission, which are available on the SEC's website at http://www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. CRISPR Therapeutics disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

Investor Contact:Susan Kimsusan.kim@crisprtx.com

Media Contact:Rachel EidesWCG on behalf of CRISPR617-337-4167 reides@wcgworld.com

Read more:
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results - Benzinga

Recommendation and review posted by Bethany Smith

The first manned experiments were carried out in China with CRISPR gene editing technology. In a study with cancer patients, the treatment was shown to be safe and permanent.

Scientists and researchers continue to work on CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), a gene editing technology. The first manned experiments with this gene editing technology were completed.

In these first experiments using CRISPR technology, quite promising developments took place. In the experiment, it was revealed by the researchers that the treatment was safe and permanent.

Cancer treatment with CRISPR:A team led by You Lu from West China Hospital applied CRISPR to take the immune cells of people with lung cancer to neutralize a gene called PD-1. The PD-1 protein usually sends signals to the immune cells to hold the attacks from the bodys own tissues, but the active PD-1 also extends the gates to spread the cancer.

The team then injected each participant with a modified version of their own immune cells. The participants experienced quite mild side effects. In addition, potentially dangerous gene mutations from gene regulation, the greatest fear of researchers, were very limited.

These cells, regulated by CRISPR, remained in the blood for at least four weeks, and this also showed that the effects of the strategy could be permanent, but this experiment in China was conducted with only 12 people with cancer. The authors of the article called for more comprehensive studies with newer gene editing systems. Many CRISPR based experiments guided this study, some of which have already been reported.

Read this article:
The Treatments Carried Out With CRISPR Have Been Proved To Be Safe For People - Somag News

Recommendation and review posted by Bethany Smith

BAILARD, INC. bought a fresh place in CRISPR Therapeutics AG (NASDAQ:CRSP). The institutional investor bought 53.0 thousand shares of the stock in a transaction took place on 3/31/2020. In another most recent transaction, which held on 3/31/2020, FRONTIER CAPITAL MANAGEMENT CO. bought approximately 38.5 thousand shares of CRISPR Therapeutics AG In a separate transaction which took place on 3/31/2020, the institutional investor, IMA WEALTH, INC. bought 38.3 thousand shares of the companys stock. The total Institutional investors and hedge funds own 54.30% of the companys stock.

In the most recent purchasing and selling session, CRISPR Therapeutics AG (CRSP)s share price decreased by -0.99 percent to ratify at $52.00. A sum of 1315673 shares traded at recent session and its average exchanging volume remained at 993.63K shares. The 52-week price high and low points are important variables to concentrate on when assessing the current and prospective worth of a stock. CRISPR Therapeutics AG (CRSP) shares are taking a pay cut of -29.73% from the high point of 52 weeks and flying high of 60.99% from the low figure of 52 weeks.

CRISPR Therapeutics AG (CRSP) shares reached a high of $53.615 and dropped to a low of $49.33 until finishing in the latest session at $53.25. Traders and investors may also choose to study the ATR or Average True Range when concentrating on technical inventory assessment. Currently at 3.32 is the 14-day ATR for CRISPR Therapeutics AG (CRSP). The highest level of 52-weeks price has $74.00 and $32.30 for 52 weeks lowest level. After the recent changes in the price, the firm captured the enterprise value of $2.36B, with the price to earnings ratio of 53.55. The liquidity ratios which the firm has won as a quick ratio of 17.30, a current ratio of 17.30 and a debt-to-equity ratio of 0.00.

Having a look at past record, were going to look at various forwards or backwards shifting developments regarding CRSP. The firms shares fell -0.76 percent in the past five business days and grew 17.41 percent in the past thirty business days. In the previous quarter, the stock fell -4.06 percent at some point. The output of the stock increased 15.94 percent within the six-month closing period, while general annual output gained 29.39 percent. The companys performance is now negative at -14.62% from the beginning of the calendar year.

According to WSJ, CRISPR Therapeutics AG (CRSP) obtained an estimated Overweight proposal from the 17 brokerage firms currently keeping a deep eye on the stock performance as compares to its rivals. 2 equity research analysts rated the shares with a selling strategy, 4 gave a hold approach, 11 gave a purchase tip, 0 gave the firm a overweight advice and 0 put the stock under the underweight category. The average price goal of one year between several banks and credit unions that last year discussed the stock is $74.25.

CMS Energy Corporation (CMS) shares on Wednesdays trading session, dropped -3.29 percent to see the stock exchange hands at $57.26 per unit. Lets a quick look at companys past reported and future predictions of growth using the EPS Growth. EPS growth is a percentage change in standardized earnings per share over the trailing-twelve-month period to the current year-end. The company posted a value of $2.28 as earning-per-share over the last full year, while a chance, will post $2.85 for the coming year. The current EPS Growth rate for the company during the year is 3.00% and predicted to reach at 8.21% for the coming year. In-depth, if we analyze for the long-term EPS Growth, the out-come was 5.60% for the past five years and the scenario is totally different as the current prediction is 7.30% for the next five year.

The last trading period has seen CMS Energy Corporation (CMS) move -17.22% and 24.40% from the stocks 52-week high and 52-week low prices respectively. The daily trading volume for CMS Energy Corporation (NYSE:CMS) over the last session is 2.64 million shares. CMS has attracted considerable attention from traders and investors, a scenario that has seen its volume drop -5.36% compared to the previous one.

Investors focus on the profitability proportions of the company that how the company performs at profitability side. Return on equity ratio or ROE is a significant indicator for prospective investors as they would like to see just how effectively a business is using their cash to produce net earnings. As a return on equity, CMS Energy Corporation (NYSE:CMS) produces 13.80%. Because it would be easy and highly flexible, ROI measurement is among the most popular investment ratios. Executives could use it to evaluate the levels of performance on acquisitions of capital equipment whereas investors can determine that how the stock investment is better. The ROI entry for CMSs scenario is at 5.80%. Another main metric of a profitability ratio is the return on assets ratio or ROA that analyses how effectively a business can handle its assets to generate earnings over a duration of time. CMS Energy Corporation (CMS) generated 2.60% ROA for the trading twelve-month.

Volatility is just a proportion of the anticipated day by day value extendthe range where an informal investor works. Greater instability implies more noteworthy benefit or misfortune. After an ongoing check, CMS Energy Corporation (CMS) stock is found to be 3.27% volatile for the week, while 4.28% volatility is recorded for the month. The outstanding shares have been calculated 287.81M. Based on a recent bid, its distance from 20 days simple moving average is -3.57%, and its distance from 50 days simple moving average is -6.24% while it has a distance of -7.97% from the 200 days simple moving average.

The Williams Percent Range or Williams %R is a well-known specialized pointer made by Larry Williams to help recognize overbought and oversold circumstances. CMS Energy Corporation (NYSE:CMS)s Williams Percent Range or Williams %R at the time of writing to be seated at 97.98% for 9-Day. It is also calculated for different time spans. Currently for this organization, Williams %R is stood at 98.20% for 14-Day, 67.39% for 20-Day, 51.47% for 50-Day and to be seated 51.47% for 100-Day. Relative Strength Index, or RSI(14), which is a technical analysis gauge, also used to measure momentum on a scale of zero to 100 for overbought and oversold. In the case of CMS Energy Corporation, the RSI reading has hit 45.34 for 14-Day.

See the article here:
Solid Income Opportunity With CRISPR Therapeutics AG (CRSP) and CMS Energy Corporation (CMS) - BOV News

Recommendation and review posted by Bethany Smith

CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its first quarter 2020 financial results and operational highlights in a conference call on May 7, 2020 at 8 a.m. ET.

To join the call:

A replay of the call will be available through the Events and Presentations page of the Investors & Media section of the companys website at http://www.intelliatx.com, beginning on May 7, 2020 at 12 p.m. ET.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases, or can replace patients diseased cells. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com and follow us on Twitter @intelliatweets.

Intellia Contacts:

Investor Contact:Lina LiAssociate Director, Investor Relations+1 857-706-1612lina.li@intelliatx.com

Media Contact:Jennifer Mound SmoterSenior Vice President, External Affairs & Communications+1 857-706-1071jenn.smoter@intelliatx.com

Continued here:
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2020 Earnings and Company Updates - Yahoo Finance

Recommendation and review posted by Bethany Smith

ETF Trends CEO Tom Lydon discussed the ARK Genomic Revolution Multi-Sector Fund (ARKG)on this weeks ETF of the Week podcast with Chuck Jaffe on the MoneyLife Show.

The ARK Genomic Revolution ETF (ARKG) is an actively-managed fund from the team at ARK Invest that tries to pick the companies best positioned to profit from advancements in energy, automation, manufacturing, materials, and transportation.

ARKG is an outperforming biotech ETF. As far as 1-month performances: ARKG is +43.7% versus the benchmark Nasdaq Biotechnology Index at +26.4%. Year-to-date, ARKG is +15.7% versus Nasdaq Biotechnology Index at +2.4%.

Concerning today, there is short-term support from the hope of a viable COVID-19 drug. For example, Pluristem (PSTI) surged on news that it had treated seven severely ill patients with COVID-19 in Israel with its allogeneic placental expanded (PLX) cells, with a survival rate of 100%, and It has treated at least one patient in the United States as well.

ARKG capitalizes on innovative, specialized drugs that are being developed by many overlooked names. Iovance (IOVA) climbed after it announced it would present data on its Phase 1 Study Combining Tumor-Infiltrating Lymphocytes (TIL) and Nivolumab in Non-Small Cell Lung Cancer. Compugen (CGEN) jumped on news that the company will present potentially positive updates on its ongoing Phase 1 immuno-oncology clinical trial evaluating COM701.

Looking at the long-term outlook, ARKG includes companies that merge healthcare with technology and capitalize on the revolution in genomic sequencing. These companies try to understand better how biological information is collected, processed, and applied by reducing guesswork and enhancing precision, restructuring health care, agriculture, pharmaceuticals, and improving our quality of life.

The convergence of Artificial Intelligence (AI), Next Generation DNA Sequencing (NGS) and CRISPR gene-editing has the potential to boost the efficiency of drug development radically. Breakthroughs in genomic science can present new treatments to help patients recover from what were once believed to be incurable afflictions.

For the record, the global genomics market was worth $851.96 million in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 14.71% and reach $1.5 billion by 2023. Rising government funds for research on genomics drives the growth of the single-cell genomics market. The government funding focuses on efforts to resolve the complexity of the human genome, the genomic basis of human health and disease, and ensure that genomics is used safely to enhance patient care and benefit society through government, public and private institutions.

Related:ETF of the Week: ProShares Long Online/Short Stores ETF (CLIX)

Scientists have identified more than 50,000 genetic diseases caused by single-gene mutations, many of which are likely to be treated through genomic approaches, including several methods that have already begun to receive FDA approval. Looking ahead, CRISPR-based innovations to accelerate given the technologys ease of use, cost-efficacy, a growing body of research surrounding its safety and AI-powered CRISPR nuclease selection tools. CRISPR could also be utilized to address some of the most prominent healthcare problems, which opens up a significant investment opportunity in monogenic diseases.

Bolstering the case for ARKG over the long-term is the importance of genomics in an array of clinical trials. Drug development companies are making clinical trials more efficient by using NGS to find and enroll patients likely to respond. Half of the clinical trials and 80% of oncology trials now collect genetic information. ARK believes that clinical trials using genetic diagnostics will result in fewer failed drugs and will increase capital efficiency.

Go here to read the rest:
ETF of the Week: ARK Genomic Revolution Multi-Sector Fund (ARKG) - ETF Trends

Recommendation and review posted by Bethany Smith

WOBURN, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it has obtained a positive response from USDA-APHISs Biotechnology Regulatory Services (BRS) for its CRISPR genome-edited C3007 trait in Camelina sativa plant lines designed to increase oil content. Yield10s submission along with the USDA-APHIS BRS response is posted on theUSDAs website.

In January 2020, Yield10 submitted an Am I Regulated? letter to the BRS, requesting confirmation of the regulatory status for Camelina plant lines containing the Companys novel, CRISPR genome-edited C3007 trait. The positive USDA-APHIS response came in the form of a published letter indicating that the plant lines do not meet the definition of a regulated article under 7 CFR Part 340.

This clarification of the regulatory status under USDA-APHIS guidelines accelerates the path for Yield10 to conduct field trials of the CRISPR genome-edited C3007 plants in the United States in the 2020 growing season. The plant lines may still be subject to regulation by the U.S. Environmental Protection Agency (EPA) or the U.S. Food and Drug Administration (FDA).

Receiving a positive response from USDA-APHIS for our CRISPR genome-edited C3007 lines is a critical milestone within our development program and facilitates the transition of lines with this trait to field testing this year, said Dr. Kristi Snell, Ph.D., Chief Science Officer of Yield10 Bioscience. Initial studies with C3007 have demonstrated potential for increased oil content, and the next step of testing this trait under field conditions will help us to characterize its performance and role in boosting oil content in Camelina and other oilseed crops.

The ability to increase oil content in specialty oilseed crops like Camelina has the potential to make a significant impact in the supply of omega fatty acid containing oils, to human nutrition and aquaculture feed markets. Further, the continued analysis of C3007 and its role as a key regulator of oil content in Camelina may also enable this trait to be used to increase production of edible oils in other major oilseed crops such as soybean and canola.

Once again, we appreciate both the speed and the transparency in which USDA-APHIS reviewed our letter and the data we provided, which has enabled us to plan our first field trials with this trait in 2020, said Dr. Oliver Peoples, Chief Executive Officer of Yield10 Bioscience. It is this sound, science-based regulatory framework that we believe is so important to the successful development and commercialization of new technologies for agriculture to increase crop performance, as well as other efforts to address sustainable global food security.

Yield10 licensed C3007 from the University of Missouri (MU) in 2018. The protein encoded by C3007, also known as BADC, is a novel regulator of the enzyme acetyl-CoA carboxylase (ACCase), the key enzyme for producing fatty acids for oil biosynthesis. In pilot studies conducted by MU researchers, reducing activity of the protein encoded by C3007 resulted in significantly increased oil content in seeds.Yield10 researchers have successfully used CRISPR to inactivate a number of the C3007 gene copies in Camelina and have seen clear evidence of increased oil content in some lines in laboratory studies. The use of CRISPR to deploy the trait may enable an expedited timeline for development and commercialization within the U.S. market.

The CRISPR genome-edited C3007 trait could deliver significant economic value by changing the value equation for the commercialization of identity preserved, specialty oilseed crops where the key value-driver is oil content with improved nutritional profiles for human consumption or for aquaculture feed or industrial markets. These traits may also be used to increase production of edible oils in major oilseed crops such as soybean and canola.

AboutYield10 Bioscience

Yield10 Bioscience, Inc. is an agricultural bioscience company developing crop innovations to improve crop yields and enhance sustainable global food security. The Company utilizes its proprietary GRAIN (Gene Ranking Artificial Intelligence Network) gene discovery platform to identify gene targets to improve yield performance and value in major commercial food and feed crops. Yield10 uses its Camelina oilseed platform to rapidly evaluate and field test new trait leads enabling the translation of promising new traits into the major commercial crops. As a path toward commercialization, Yield10 is pursuing a partnering approach with agricultural companies to drive new traits into development in crops such as canola, soybean and corn. The Company is also developing Camelina as a platform crop for producing nutritional oils and specialty products such as PHA biomaterials for use in water treatment applications. Yield10 is headquartered in Woburn, MA and has an Oilseeds Center of Excellence in Saskatoon, Canada.

For more information about the company, please visitwww.yield10bio.com, or follow the Company onTwitter,FacebookandLinkedIn.

(YTEN-G)

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical, including, without limitation, statements regarding the Company's ability to conduct field testing of C3007 in Camelina plant lines in 2020, the possibility that testing this trait under field conditions will help us to characterize the performance of the trait and its role in boosting oil content in Camelina and other oilseed crops, the ability of C3007 to increase oil content in Camelina and other oilseed crops, the potential to make a significant impact in the supply of omega fatty acid containing oils to human nutrition and aquaculture feed markets, the potential for the trait to be used to increase production of edible oils in other major oilseed crops such as soybean and canola, the potential for an expedited timeline for development and commercialization within the U.S. market, the possibility for the trait to deliver economic value in other areas, and the possibility of translating promising new traits into the major commercial crops, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including the risks and uncertainties detailed in Yield10 Bioscience's filings with the Securities and Exchange Commission. Yield10 assumes no obligation to update any forward-looking information contained in this press release or with respect to the matters described herein.

Contacts:Yield10 Bioscience:Lynne H. Brum, (617) 682-4693,LBrum@yield10bio.com

Investor Relations Contact:Bret Shapiro, (561) 479-8566,brets@coreir.comManaging Director, CORE IR

Media Inquiries:Eric Fischgrund,eric@fischtankpr.comFischTank Marketing and PR

Read this article:
Yield10 Bioscience Obtains Positive Response from USDA-APHIS on Regulatory Status of its CRISPR Genome-Edited C3007 Trait in Camelina, Paving the Way...

Recommendation and review posted by Bethany Smith

Scientists are trying to tackle the lack of diversity seen in genomics research, but even ambitious efforts, like the NIHs All of Us program, often fall short, especially when it comes to the inclusion of Indigenous communities. This is one of the reasons why the Decolonize DNA Day conference is taking place on April 24th, one day before the National DNA Day.

Traditionally, National DNA Day is an annual celebration of the discovery of DNA's double helix structure (1953) and the completion of the Human Genome Project (2003).

I was having conversations with colleagues on what would it mean to decolonize DNA, says Krystal Tsosie, an Indigenous (Din/Navajo) PhD student at Vanderbilt University. As an Indigenous academic, we always talk about what it means to Indigenize and re-Indigenize different disciplines of academia that have been historically more white-centred or white-dominated... and what it would mean to remove the colonial lens.

In collaboration with Latrice Landry and Jerome de Groot, Tsosie co-organized the Decolonize DNA Day Twitter conference to help re-frame narratives around DNA. Each speaker will have an hour to tweet out their "talk" and lead conversations on various topics, including how DNA ancestry testing fuels anti-Indigeneity and how to utilize emerging technologies to decolonize precision medicine.

There is a divide between people who are doing the science or the academic work, and the people who we want to inform, says Tsosie. Twitter is a great way to bridge that divide.

The Decolonize DNA Day conference is simply one effort to Indigenize genomics. Tsosie is also a co-founder of the Native BioData Consortium, a non-profit organization consisting of researchers and Indigenous members of tribal communities, focused on increasing the understanding of Native American genomic issues.

We dont really see a heavy amount of Indigenous engagement in genetic studies, which then means that as precision medicine advances as a whole [] those innovations are not going to be applied to Indigenous people, says Tsosie. How do we get more Indigenous people engaged?

Some of the answers can be found in a recent Nature Reviews Genetics perspective, penned by Indigenous scientists and communities, including those from the Native BioData Consortium. The piece highlights the actions that genomics researchers can take to address issues of trust, accountability, and equity. Recommended actions include the need for early consultations, developing benefit-sharing agreements, and appropriately crediting community support in any academic publications.

By switching power dynamics, were hoping to get genomic researchers to work with us, instead of against us, says Tsosie.

Excerpt from:
Tinkering with brain proteins may add insulation back to damaged nerve cells - Massive Science

Recommendation and review posted by Bethany Smith

You know that file you got from Ancestry or 23andMe that contains a digital copy of your entire genetic code? Imagine that you upload it to a site, and five minutes later it spits out a report. Bad news it says your risk from the coronavirus is a glaring red HIGHER, meaning that according to a potpourri of genetic markers, youre more likely to have a severe, potentially deadly case of COVID-19.

Thats the idea behind a free genetic analysis offered by Sequencing.com, a genetic testing company thats offering personalized, DNA-based coronavirus warnings.

A person who looks to be low risk on a non-genetic level or seems like they could be pretty okay if they get COVID-19, we know that their genes are putting them on the path to a more severe disease, Sequencing CEO and clinical geneticist Brandon Colby told Futurism.

One of the major challenges of the coronavirus pandemic has been identifying whos at a greater risk for a disease that remains difficult to treat. At first, the outbreak seemed to be most dangerous for the elderly or people with underlying health conditions. But over time, more reports emerged of younger, healthier people coming down with severe and sometimes fatal cases.

Colbys goal is to personalize coronavirus testing by providing reports catered specifically to a individuals genetic code. With that, the screenings could bring to light warnings signs that might have previously flown under the radar for patients who otherwise seem healthy.

Colby told Futurism that he hopes the reports will convince people with high genetic risk factors to exercise greater caution. And if they do start to feel sick, he says, the report could spur them to seek treatment immediately.

That person may have genes that put them at high risk, and thats really the power of this report, Colby told Futurism. Without this report, that would have been a major question.

While clinical trials about how to best treat COVID-19 are only beginning to emerge, geneticists have already learned much about the structure, genetic code, and biological mechanisms of the virus that causes it, SARS-CoV-2. Colby and his team used that research to develop their predictive reports.

Because SARS-CoV-2 is so genetically similar to SARS-CoV-1, the coronavirus that causes SARS, the Sequencing team also pulled from the far more expansive body of research on that virus as well, since the same genes seem to be linked to a greater risk of infection and more severe symptoms of both diseases.

This research is still preliminary and this analysis is based on preliminary genetic associations, Colby said. If the pandemic was not such a crisis, then this would be something that we would want more research to come out upon. We would probably put this up there in a beta format, and that would be very clear.

But due to the crisis, the urgency, we are utilizing these preliminary studies and making sure that people understand that these are preliminary, he added. Were utilizing what information we currently have available to make it useful at a time when its needed.

Supplementing their research with existing studies on the SARS virus may make for a more robust tool, but genetic experts werent entirely convinced by the idea of an online genetic test for COVID risk.

I think the key here is that there are both genetic and environmental factors that contribute to an individuals personal susceptibility, Boston University geneticist Shoumita Dasgupta, whos unaffiliated with Sequencing, told Futurism. We know this from other pathogens as well. Neither one alone will be enough to be completely protective, but the combination of public health measures and biomedical research on genetic risk factors can together help us navigate our way out of this situation.

Genetics rarely gives you a 100 percent foolproof predictive ability, Dasgupta added.

Certainly, comparative genomics can give insight from how genes work in other systems, but since viruses evolve quickly, its possible that those components may work together slightly differently in the novel coronavirus, Dasgupta added.

Because genes cant possibly tell the whole story, Sequencings report also weighs non-genetic risk factors, like age, smoking habits, and existing medical conditions, which Dasgupta described as a good start. Colby told Futurism that even more environmental factors, like stress, will be included in a major update to the reports expected to go live on Friday.

Colby said that his team will add new findings as they encounter them, making the reports more accurate and robust. Anyone who got a genetic profile from Sequencing might get a notification in the future that their report has changed as new research comes in, especially after that new update.

Even with the knowledge that these reports are based on preliminary findings and could change just as the pandemic continues to change and surprise us, Colby hopes that the personalized reports and warnings will inspire people to better protect themselves.

If you dont know that youre at very high risk, you think, Hey Im 30 years old, I dont have any health problems, I dont smoke, Im gonna go shopping today. Im gonna go outside and potentially expose myself, that decision may be altered once you go and see these reports, Colby said.

Read the original post:
Free DNA Test Claims to Warn Whether COVID Is Likely to Kill You - Futurism

Recommendation and review posted by Bethany Smith

Idaho Department of Fish and Game recently confirmed that tracks near Grangeville came from a grizzly bear, a species not common in that part of the state, according to an agency news release.

The tracks were spotted April 18 about seven miles south of Grangeville in the Fish Creek Meadows area, officials said. A hair sample was collected near the tracks and sent to a lab for genetic testing, but results won't be available for several months.

"We don't know if it's going to stay," said Jon Rachael, state wildlife manager for Fish and Game, in a phone interview. "We don't know if it's still there now." According to Fish and Game, it's not the first instance of a bear in the region. A hair sample was collected near White Bird Creek, southwest of Grangeville, in spring of 2019. DNA testing of the sample showed that animal was a young male grizzly that had been radio-collared as a yearling near Idaho's border with Canada in 2017. The bear's collar had fallen off in 2018, so no tracking data was available last year.

"If confirmed as the same bear, this bear is now 4 years old, and it has traveled several hundred miles through Idaho and Montana without any known conflict with people," Fish and Game said in the news release.

Experts say grizzly bears, considered an endangered species in the Lower 48 of the United States, have been expanding their territory in Idaho, Wyoming and Montana for the last decade. Last summer, a male grizzly wearing a tracking collar headed south into the Selway-Bitterroot Wilderness Area, where grizzlies hadn't been seen in nearly a century.

"We don't have a lot of indication of grizzly bears in that area," Rachael said.

Last fall, a hunter captured images on a game camera of what he believes is a grizzly bear in the Newsome Creek area west of Elk City. That's only about 21 miles from Fish Creek Meadows, where Fish and Game found grizzly tracks last weekend. Fish and Game took DNA samples from bear scat in the area, but the results came back positive for a black bear. Rachael said it's possible the animal in the photo was a grizzly and the scat tested belonged to a different animal. He said it's also possible the bear in the photo is the same one that left tracks near Grangeville.

U.S. Fish and Wildlife Service maps from 2018 show grizzly bears are known to be in eastern Idaho near the border of Wyoming, where they sometimes roam from Yellowstone National Park. The bears are also known to be in far North Idaho near the Canadian border.

Visit The Idaho Statesman (Boise, Idaho) at http://www.idahostatesman.com

More here:
Are Grizzly Tracks Near Grangeville From Same Bear Seen Nearby Last Year? - bigcountrynewsconnection.com

Recommendation and review posted by Bethany Smith